BiotechTube

NKTR-102 + Treatment of Physician's Choice (TPC)

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
72
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Locally Recurrent Breast Cancer

Conditions

Locally Recurrent Breast Cancer, Metastatic Breast Cancer

Trial Timeline

Dec 1, 2011 โ†’ Jun 1, 2016

NCT ID
NCT01492101

About NKTR-102 + Treatment of Physician's Choice (TPC)

NKTR-102 + Treatment of Physician's Choice (TPC) is a phase 3 stage product being developed by Nektar Therapeutics for Locally Recurrent Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01492101. Target conditions include Locally Recurrent Breast Cancer, Metastatic Breast Cancer.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01492101Phase 3Completed

Competing Products

20 competing products in Locally Recurrent Breast Cancer

See all competitors
ProductCompanyStageHype Score
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
52
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
52
NBTXR3NanobiotixPhase 1/2
36
Tadalafil + GemcitabineEli LillyPhase 1
33
SPYK04Chugai PharmaceuticalPhase 1
33
LUNA18 + CetuximabChugai PharmaceuticalPhase 1
33
Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3
77
Trastuzumab Deruxtecan + Cisplatin + Carboplatin + Pembrolizumab + PemetrexedDaiichi SankyoPhase 3
77
T-DXd + Durvalumab + Cisplatin + Carboplatin + Pemetrexed + Volrustomig + RilvegostomigDaiichi SankyoPhase 1
33
ASP2998 + Pembrolizumab + Enfortumab Vedotin + CarboplatinAstellas PharmaPhase 1/2
41
zolbetuximabAstellas PharmaPre-clinical
23
enfortumab vedotin + pembrolizumabAstellas PharmaPhase 2
52
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
77
enfortumab vedotin (EV)Astellas PharmaPre-clinical
23
zolbetuximabAstellas PharmaPre-clinical
23
zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3
77
ASP3082Astellas PharmaPhase 2
52
zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + PlaceboAstellas PharmaPhase 3
77
ASP1948Astellas PharmaPhase 1
33
Camrelizumab + SOX (oxaliplatin + Teggio) /XELOX (oxaliplatin + capecitabine )Sun PharmaceuticalPhase 2
52

Other Products from Nektar Therapeutics

NKTR-102 + Eribulin + Ixabepilone + Vinorelbine + Gemcitabine + Paclitaxel + Docetaxel + Nab-paclitaxelPhase 3
72
NKTR-181 BID tablets + Placebo to match NKTR-181 BID tabletsPhase 3
72
NKTR-181 BID tabletsPhase 3
72
NKTR-255 at 1.5 ยตg/kg + NKTR-255 at 3.0 ฮผg/kg + NKTR-255 at 3.0/6.0 ฮผg/kgPhase 2/3
60
aerosolized vancomycin or gentamicinPhase 2
47